Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 201 - 220 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Equivocal Response in ACLF Trial; Lowering Target to $12
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Takeaways from Investor Meetings; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Corporate Access Event
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
3Q Recap; Preparing for a Busy Year of Trial Readouts in 2015; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
IN AASLD Late-Breaker, Emricasan Single Dose Rapidly Reduces Biomarkers
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
2Q14; NASH Trial Results Delay is a Non-Issue; Affirm Buy
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
FLINT Data Highlights Potential for Disease-Modifying Activity in NASH
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
We assume coverage with a Buy rating and $19.00 price target
Provider: Roth Capital Partners, Inc.